| 30.04 13:22 | dpa-AFX: Incyte Corporation Q1 Profit Increases, but misses estimates |
| 30.04 13:11 | dpa-AFX: *INCYTE Q1 GAAP EPS $0.75; NON-GAAP EPS $0.64 |
| 30.04 13:00 | dpa-AFX: Incyte Q1 24 Earnings Conference Call At 8:00 AM ET |
| 23.04 14:14 | dpa-AFX: Incyte To Buy Privately Held Escient Pharma |
| 23.04 13:40 | dpa-AFX: *INCYTE TO ACQUIRE ESCIENT AND ITS ASSETS FOR $750 MLN PLUS ESCIENT'S NET CASH REMAINING |
| 01.04 15:10 | dpa-AFX: CMS To Receive License To Develop, Commercialize Povorcitinib In China And Southeast Asia |
| 01.04 14:59 | dpa-AFX: *CMS, INCYTE ANNOUNCE COLLABORATION AND LICENSE DEAL FOR POVORCITINIB IN CHINA AND SOUTHEAST ASIA |
| 28.02 03:25 | dpa-AFX: Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment |
| 13.02 13:35 | dpa-AFX: Incyte Q4 Adj EPS Misses Estimates, But Revenues Top |
| 13.02 13:20 | dpa-AFX: *INCYTE Q4 GAAP NET INCOME $201.1 MLN; NON-GAAP NET INCOME $239.1 MLN LAST YEAR |
| 13.02 13:19 | dpa-AFX: *INCYTE Q4 TOTAL GAAP REVENUES $1.01 BLN VS $926.7 MLN LAST YEAR |
| 13.02 13:17 | dpa-AFX: Incyte Corporation Q4 Profit Increases, but misses estimates |
| 13.02 13:06 | dpa-AFX: *INCYTE Q4 GAAP EPS $0.89; NON-GAAP EPS $1.06 |
| 13.02 13:00 | dpa-AFX: Incyte Q4 23 Earnings Conference Call At 8:00 AM ET |
| 06.02 15:59 | dpa-AFX: ROUNDUP 2: Novartis will Morphosys schlucken - Zugriff auf Hoffnungsträger |
| 06.02 15:59 | ROUNDUP 2: Novartis will Morphosys schlucken - Zugriff auf Hoffnungsträger |
| 06.02 15:54 | dpa-AFX: ROUNDUP 2: Novartis will Morphosys schlucken - Zugriff auf Hoffnungsträger |
| 06.02 02:23 | dpa-AFX: MorphoSys Agrees To Be Acquired By Novartis For EUR 2.7 Bln |
| 30.01 14:46 | dpa-AFX: Agilent, Incyte To Collaborate On CDx Development Programs |
| 08.01 15:30 | dpa-AFX: Incyte To Present At J. P. Morgan Healthcare Conference; Webcast At 10:30 AM ET |
|
|
